In the last trading session, 1.22 million shares of the Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) were traded, and its beta was 1.72. Most recently the company’s share price was $3.37, and it changed around $0.17 or 5.31% from the last close, which brings the market valuation of the company to $239.64M. ZNTL currently trades at a discount to its 52-week high of $21.34, offering almost -533.23% off that amount. The share price’s 52-week low was $2.83, which indicates that the current value has risen by an impressive 16.02% since then. We note from Zentalis Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.25 million shares, with the 3-month average coming to 1.81 million.
Zentalis Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.11. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 6 recommended ZNTL as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Instantly ZNTL has showed a green trend with a performance of 5.31% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.78 on recent trading dayincreased the stock’s daily price by 10.85%. The company’s shares are currently down -77.76% year-to-date, but still down -10.13% over the last five days. On the other hand, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is 4.01% up in the 30-day period. We can see from the shorts that 11.7 million shares have been sold at a short interest cover period of 16.42 day(s).
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 66.3% from its current value. Analyst projections state that ZNTL is forecast to be at a low of $4 and a high of $55.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Zentalis Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -77.65 percent over the past six months and at a 34.00% annual growth rate that is well above the industry average of 17.60%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -50.05%.
ZNTL Dividends
Zentalis Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in November.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.48% of Zentalis Pharmaceuticals Inc shares, and 108.16% of them are in the hands of institutional investors. The stock currently has a share float of 112.05%. Zentalis Pharmaceuticals Inc stock is held by 206.0 institutions, with MATRIX CAPITAL MANAGEMENT COMPANY, LP being the largest institutional investor. By 2024-06-30, it held 19.6902% of the shares, which is about 13.96 million shares worth $57.1 million.
FMR LLC, with 12.2383% or 8.68 million shares worth $35.49 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
